Aspergillus species cause a range of respiratory diseases in humans. While immunocompromised patients are at risk for the development of invasive infection with these opportunistic molds, patients with underlying pulmonary disease can develop chronic airway infection with Aspergillus species. These conditions span a range of inflammatory and allergic diseases including Aspergillus bronchitis, allergic bronchopulmonary aspergillosis, and severe asthma with fungal sensitization. Animal models are invaluable tools for the study of the molecular mechanism underlying the colonization of airways by Aspergillus and the host response to these non-invasive infections. In this review we summarize the state-of-the-art with respect to the available animal models of noninvasive and allergic Aspergillus airway disease; the key findings of host-pathogen interaction studies using these models; and the limitations and future directions that should guide the development and use of models for the study of these important pulmonary conditions.
Introduction
Aspergillus species are environmental moulds that reproduce through the production of airborne spores. These ubiquitous spores are so abundant that it is estimated that the average human inhales hundreds of Aspergillus conidia daily. 1 Host immunity and the pulmonary microenvironment are critical factors in determining the outcome of this daily exposure. In healthy individuals with normal lungs, conidia are easily removed by bronchial mucociliary action or are phagocytized and killed by resident pulmonary macrophages and these individuals do not manifest any infectious or allergic symptoms. Patients with defects in cell-mediated immunity, including those with neutropenia due to cytotoxic chemotherapy, or T-cell dysfunction due to corticosteroid or other immunosuppressive therapy are at risk of developing acute invasive aspergillosis characterized by hyphal invasion of lung tissues and even dissemination to other organs. 2, 3 However, in patients with Aspergillus induced airway diseases underlying chronic respiratory disorders, such as chronic obstructive pulmonary disease, post-pulmonary tuberculosis, cystic fibrosis (CF) or bronchiectasis, alterations in the pulmonary microenvironment can permit the development of local airway infection with Aspergillus. 4, 5 As a result, as many as 50% of patients with CF will have respiratory cultures positive for Aspergillus species during the course of their illness. 6 Aspergillus infections in patients with chronic lung disease include chronic pulmonary aspergillosis, which encompasses a spectrum of subacute to chronic invasive pulmonary infections, as well as noninvasive airway diseases including asymptomatic colonization, Aspergillus bronchitis, fungal asthma, and allergic bronchopulmonary aspergillosis (ABPA) (Fig. 1) . 7 These noninvasive airway diseases, and the development of animal models for their study will be the focus of the present review.
Allergic bronchopulmonary aspergillosis
ABPA is the best studied of the noninvasive Aspergillus airway infections and is characterized by a severe hypersensitivity response to Aspergillus fumigatus antigens released during airway colonization of susceptible patients.
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This over exuberant immune response manifests as a constellation of immunological findings including peripheral blood eosinophilia, immediate cutaneous reactivity to A. fumigatus antigens, elevated total serum immunoglobulin E (IgE), precipitating antibody to A. fumigatus, elevated specific serum IgE and immunoglobulin G (IgG) antibodies to A. fumigatus antigens and eosinophilic airway inflammation. 8, 9 Clinically ABPA presents with worsening reactive airway disease, mucous plugging and the development of central bronchiectasis. New diagnostic and staging criteria for ABPA have recently been proposed in order to facilitate consensus-based clinical studies.
Severe asthma with fungal sensitization (SAFS) Aspergillus species are also one of the fungal species associated with the SAFS hypersensitivity syndrome. This condition, first proposed in 2006, is characterized by severe asthma with sensitization against fungal allergens such as Alternaria spp., Cladosporium spp., Candida albicans, or Aspergillus spp. 10 SAFS is distinguished from ABPA by the lack of pulmonary infiltration, bronchiectasis, and mucus plugging. 10 As SAFS affects as many as 6.5 million people worldwide, 11 it is arguably the most common airway disease associated with A. fumigatus. It is controversial whether this condition represents sensitization to repeated exposure of fungal antigens alone or a response to airway infection similar to ABPA. Two clinical trials of antifungal therapy have yielded conflicting results, with an early trial of itraconazole reporting improvement in quality of life scores and pulmonary function tests, 12 while a more recent trial found that voriconazole was not effective in this population.
13
Aspergillus bronchitis Although ABPA is the best-known complication of Aspergillus airway infection, the majority of patients who develop documented airway infection with Aspergillus species will not develop ABPA. 11 Although many of these patients remain relatively asymptomatic, some studies have reported that recovery of Aspergillus species from respiratory cultures is associated with an accelerated decline in pulmonary function and/or more frequent hospitalizations, although this finding has not been consistent across centers or patient populations. 14, 15, 16 More recently, the term Aspergillus bronchitis has been suggested for patients with evidence for Aspergillus sp. growing within the airways and chronic, non-allergic pulmonary symptoms in order to distinguish them from those with asymptomatic colonization or fungal hypersensitivity disease like SAFS and ABPA. 17, 18 Diagnostic criteria to distinguish Aspergillus bronchitis from asymptomatic colonization have been proposed, 17, 18 however validation of these criteria as predictors of long-term outcomes in large cohorts remains to be performed.
Animal models of Aspergillus-mediated airway diseases
A lack of experimental systems has limited our understanding of the pathobiology and management of noninvasive airway disease due to Aspergillus species. Animal models are useful research tools to bridge the gap between in vitro and clinical studies, and are essential for understanding of pathophysiology, evaluating pharmacology and efficacy of therapy. Animal models of invasive pulmonary aspergillosis have been invaluable for the study of this condition and have permitted the characterization of fungal virulence factors, host determinants of susceptibility to infection, novel diagnostic methods, and therapies. 19, 20 These models rely on either immunosuppressive therapy to render mice susceptible to infection, or the use of an extremely high inoculum to induce transient infection in immunocompetent mice. All of these techniques result in short term, acute pulmonary infection in mice with normal lungs. 20, 21 As a result, these models are of limited use for studying host defense, allergic responses, or therapy of noninvasive fungal conditions in pre-existing lung diseases. This review will summarize the current status of efforts to develop animal models for the study of noninvasive Aspergillus-mediated pulmonary diseases, and highlight gaps in our available models.
Animal models of Aspergillus-induced pulmonary hypersensitivity
The best-developed animal models of Aspergillus airway disease have focused on the use of Aspergillus antigens or extracts to induce allergic and inflammatory airway responses. The first reports of pulmonary hypersensitivity models using Aspergillus components were in the 1990 s, in which mice were sensitized with intranasal administration of culture filtrate and mycelial extracts of A. fumigatus twice weekly for 4 weeks. 22, 23 Characterization of the immune response to this exposure revealed the production of specific antibodies against A. fumigatus antigens in the blood, elevated IgE, and eosinophilia in peripheral blood, 23, 24 lung, 24 and bone marrow, 22, 23 thus establishing that this challenge induces pulmonary hypersensitivity and allergic responses to A. fumigatus. Following these seminal studies, a number of modifications to elicit Aspergillus sensitization have been reported (Table 1) . 22, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Other groups have reported the use of sensitization with nonfungal antigens either alone or in combination with Aspergillus-derived material. Sensitization with Dermatophagoides farina allergen 39, 45 and an antigen cocktail consist of A. fumigatus antigens and ovalbumin; and A. fumigatus, house dust mite, and Alternaria antigens resulted in the induction of robust eosinophilic airway inflammation, increased levels of pulmonary Th2 cytokines, and increased airway hyperresponsiveness.
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These approaches have not been directly compared with standard A. fumigatus sensitization alone. The antigen cocktail of D. farina, ragweed, and A. fumigatus antigens indicated synergetic effects in dendritic cell signaling and T-cell stimulation as compared with single antigen sensitization. 46 Collectively these studies suggest that diverse A. fumigatus preparations induce a similar allergic response, although whether this represents the dominant effects of a single allergen, or a shared response to diverse fungal antigens remains unknown.
Modifications to the sensitization and challenge schedules have also been reported (Table 1) . Early studies comparing intraperitoneal and intranasal injections of A. fumigatus antigens reported that intranasal inoculation was associated with higher levels of anti-Aspergillus antibodies than with intraperitoneal injection. Further, eosinophilia and pulmonary eosinophil recruitment were observed only with intranasal administration of antigen. 24 Delivery of A. fumigatus conidia by inhalation in A. fumigatus antigen sensitized mice resulted in increased recruitment of eosinophils and lymphocytes, as compared to an intratracheal challenge model in which macrophages and neutrophil recruitment were more prominent. 38, 47 More recently the pulmonary immune response to repeated conidia exposure without other sensitization has been explored. In this model, C57BL/6 mice received 2 × 10 6 conidia weekly by intranasal inoculation. 44 Immune profiling was performed after two, four, and eight intranasal challenges. Approximately 99% of conidia were cleared within 24 hours after inoculation, and repeated exposure to A. fumigatus conidia did not result in hyphal growth or accumulation of conidia with time. 44 The pulmonary immune response reached its maximal level after four challenges and was characterized by increased levels of pulmonary eosinophils, goblet cell metaplasia, and Th2 cytokine production, which was accompanied by sustained interleukin 17 (IL-17) expression that persisted even after the Th2 response began to resolve. 44 Other studies using this model have reported that IL-17 plays an important role in eosinophil migration into pulmonary tissues following conidial exposure, 48 and that tumor necrosis factor-α from inflammatory dendritic cells regulates lung IL-17A/IL-5 levels and the relative abundance of neutrophils and eosinophils within the airways.
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Animal models of Aspergillus-induced hypersensitivity disease as tools for the study of host-pathogen interactions A limited number of studies have examined the role of specific fungal factors in the pathogenesis of Aspergillus airway hypersensitivity disease. In a seminal study examining the role of Aspergillus sensitization in pediatric asthma, investigators identified that a fungal protease produced by hyphae of Aspergillus niger was present in dust samples from households of asthmatic patients. 49 In contrast to challenge studies with A. fumigatus conidia, intranasal challenge with 4 × 10 5 conidia of A. niger resulted in germination of conidia and transient hyphal colonization of the airways. 49 Colonization was necessary for the development of airway hypersensitivity pulmonary eosinophil recruitment, as these responses were not observed when mice were challenged with killed conidia. 49 Most importantly, challenge of mice with conidia from a protease-deficient strain of A. niger also failed to induce airway hypersensitivity, thus clearly implicating fungal proteases in the development of fungal allergic airways disease. 49 A more recent study in A. fumigatus strengthens the link between fungal proteases and allergic disease. 50 In this study, repeated intranasal challenge with culture filtrates derived from wild-type A. fumigatus was compared with filtrates derived from mutants deficient in the proteases Asp f 13 and Asp f 5. 50 Repeated challenge with these protease-deficient culture filtrates resulted in significantly less airway inflammation, pulmonary eosinophil recruitment and airway remodeling as compared to challenge with wild-type culture filtrates. 50 The results of these studies have established an important role for fungal proteases role in the pathogenesis of Aspergillus-induced airway hypersensitivity. A variety of mouse strains have been used to study the role of specific cytokines and cell types in pathogenesis of A. fumigatus airway hypersensitivity disease. In a model of sensitization with A. fumigatus antigens, no differences were observed in total serum IgE, Aspergillus specific IgG subclass, peripheral blood eosinophils, and lung histology between IL-4 deficient mice and wild-type BALB/c or C57BL/6 mice, suggesting this cytokine is dispensable for A. fumigatus sensitization. 51 Other transgenic mice have provided insight into the role of individual cytokines in the pathogenesis of A. fumigatus-induced airway hypersensitivity. IL-17-deficient animals displayed reduced pulmonary eosinophil recruitment in response to repeated conidia challenge, 48 and IL-6 deficient mice exhibited reduced mucus production in association with decreased IL-13 production. 37 In contrast, IL-10-deficient mice developed exaggerated airway inflammation, high levels of IL-5 and IFN-γ in bronchoalveolar lavage (BAL) fluids and increased mortality after only two doses of A. fumigatus antigen. 52 Antibody neutralization of cytokines in these models has also contributed to our understanding of the mechanism of allergic responses to Aspergillus. For example, anti-IL-4 and IL-5 antibody therapy resulted in decreased IgE levels and reduced pulmonary eosinophil recruitment in mice exposed to A. fumigatus antigens. 53 In eosinophil-deficient mice intranasally exposed with A. fumigatus antigens, Th2 lymphocyte cytokine production was impaired in the lungs, and mucus production was also reduced. 54 Collectively these studies have helped shed light on the immunopathogenesis of airway hypersensitivity to A. fumigatus and highlight the utility of animal models as tools to unravel the mechanisms of inflammation in this condition. CFTR-deficient mice have been studied in several animal models of Aspergillus airway disease. When exposed to A. fumigatus antigens, CFTR-deficient mice, as compared to wild-type, exhibited severe airway inflammation and an enhanced Th2 inflammatory response with elevated IL-4 in the lung and IgE and IgG1 in serum. 33 The mechanisms underlying this Aspergillus-induced airway inflammation in CF has been studied by several groups. CFTR-deficient mice displayed increased epithelial cell susceptibility to apoptosis, and exaggerated lymphocytic inflammation, mucin accumulation, and lung injury following a single inhalational challenge with A. fumigatus conidia. 55 The roles of IL-37 56 and IL-1 57 in the host-response to A. fumigatus have also been studied in CFTR-deficient mice in this model. Pretreatment of mice with human recombinant IL-37 had no effect on fungal burden but decreased the numbers of neutrophils in bronchoalveolar lavage fluid in association with lower expression of pulmonary myeloperoxidase, CXCL2, IL-1b, IL-17a, IL-4, and increased expression of IL-10 and IFN-γ . 56 These results suggest that IL-37 is a potent modulator of inflammation during respiratory fungal infection and allergy. A recent study of the role of the inflammasome in response to A. fumigatus challenge was performed in CFTR-deficient mice challenged with a high dose of conidia (10 7 conidia per mouse). 57 These mice displayed impaired NLRC4-dependent IL-1RA production suggesting that deficiency of this anti-inflammatory cytokine may contribute to the increased pulmonary inflammation seen in CF patients colonized with A. fumigatus. 57 Administration of recombinant IL-1RA improved inflammation and reduced fungal burden in these mice. 57 However, it is unclear if these results can be extrapolated to chronic airway A. fumigatus infection in CF given the very high inoculum used in these studies and fact that hyphal colonization was not observed in these experiments.
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Significance and limitation of Aspergillus sensitized animal models These models of Aspergillus allergic airway disease are excellent tools for the study of airway hyper-reactivity and allergic inflammation in response to conidia and specific hyphal antigens. Studies using these animal models have provided important insights into evaluating the activity of therapeutic agents for these conditions, 45, [58] [59] [60] innate immunity, [60] [61] [62] [63] [64] [65] [66] [67] B cell, T cell, and cytokine and chemokine responses against A. fumigatus. 31, 36, 37, 40, 44, 48, 52, 56, [68] [69] [70] [71] [72] 50, 73 However, important limitations of these models remain, repeated challenge with antigens, extracts, or conidia does not result in airway colonization with live hyphae, bronchiectasis, or mucus plugging, all of which are hallmarks of ABPA. Thus, these models likely more accurately reproduce Aspergillus-induced asthma or SAFS rather than ABPA or Aspergillus bronchitis.
Aspergillus airway colonization model in immunocompetent mice
The absence of airway colonization with hyphae in models of Aspergillus airway disease is an important limitation for the study of the pathophysiology of ABPA and Aspergillus bronchitis. The cell wall composition and secretome of conidia differ markedly from hyphae. 74 In fact, many of the Asp f proteins to which patients with ABPA mount an immune response are produced by hyphae and not found in resting conidia. [75] [76] [77] Further, actively growing hyphae can produce a wide range of immunoreactive secondary metabolites, such as gliotoxin, that are absent in conidia. 78, 79 The study of A. fumigatus mutants with hyphae-specific phenotypes in animal models of invasive aspergillosis has been an invaluable tool for the study of fungal virulence factors. 80 As such, the availability of an animal model in which live hyphae grow within the airways would be a useful tool for the study of host-pathogen interactions and therapeutics. One approach to the induction of airway colonization with hyphae is the infection of immunocompetent mice with conidia embedded within agar beads. This approach was first evaluated as a model of invasive pulmonary aspergillosis following noninvasive Aspergillus colonization. 81 In this study, mice infected with A. fumigatus conidia-containing agar beads developed chronic noninvasive airway infection with A. fumigatus for 6 weeks. Treatment of colonized mice with cortisone acetate 2 weeks after the infection lead to the development of invasive aspergillosis, suggesting it may be an excellent model for the study of the pathogenesis of invasive aspergillosis in patients with underlying chronic lung disease. 81 The evolution of the inflammatory and airway response to airway colonization in the agar bead model was recently reported (Fig. 2) . 82 As early as 24 hours after infection, microscopic examination of airways from infected mice revealed the presence of neutrophilic inflammation within the airways surrounding A. fumigatus-containing beads. By day 7 post-infection, the intraluminal leukocyte infiltration was also accompanied by peribronchial inflammation, composed of both neutrophils and mononuclear cells. 82 This pattern of inflammation persisted in the lungs of mice up to 28 days post-infection, the latest time point studied. 82 Pulmonary cytokine analysis from A. fumigatus bead-infected mice revealed an increase in pro-inflammatory cytokines and chemokines early in infection. 82 Evidence of a transient Th2 type response was observed only early in the course of colonization, as manifested by increased levels of IL-4, elevated IgE levels in serum, and a mild increase in airway responsiveness. 82 Pulmonary T-cell subset analysis during infection mirrored the cytokine results with an initial transient increase in IL-4-producing CD4 + T cells, followed by a rise in IL-17 by day 14, and then a predominant population of Foxp3 + T cells by day 21 to 28. A transient increase in airway hyperactivity was observed accompanying the transient Th2 response but by 28 days infected mice displayed reduced airway reactivity compared with uninfected controls. 82 It was suggested that this reduced airway sensitivity might be a consequence of regulatory T cell (Treg) activity, but this hypothesis needs to be investigated further.
The natural history and type of inflammatory response observed in the bead colonization model in C57Bl/6 mice is most similar to that of Aspergillus bronchitis. The pathology of the Aspergillus bead model and human Aspergillus bronchitis are both characterized by a predominance of chronic neutrophilic inflammation within airways colonized with hyphae of A. fumigatus and an absence of a significant allergic or hypersensitivity response. As C57Bl/6 exhibit a more polarized immune response to Aspergillus infection, it is possible that the use of more Th2 prone mouse strains, such as BALB/c 83 or mice with inducible Treg deficiency 84 may result in a model that more closely resembles ABPA.
Conclusions
Numerous studies using Aspergillus-induced hypersensitivity models have provided important insights into the pathogenesis of this condition. However, the lack of a model in which airways are colonized with live hyphae has limited the ability to study fungal virulence factors and antifungal therapies in vivo. The development of an airway colonization model provides a new tool to probe the pathogenesis of Aspergillus bronchitis. Adapting this model to hypersensitivity-prone mice or those with chronic lung disease may ultimately provide a better model of ABPA in which allergic responses to hyphal antigens produced in vivo can be studied in detail.
